Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer

Published:2015-05-20 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Wiggans Alison J¹,Cass Gemma KS¹,Bryant Andrew²,Lawrie Theresa A³,Morrison Jo⁴

Affiliation:

1. Musgrove Park Hospital; Department of Obstetrics and Gynaecology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA

2. Newcastle University; Institute of Health & Society; Medical School New Build Richardson Road Newcastle upon Tyne UK NE2 4AX

3. Royal United Hospital; Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group; Education Centre Bath UK BA1 3NG

4. Musgrove Park Hospital; Department of Gynaecological Oncology; Taunton and Somerset NHS Foundation Trust Taunton Somerset UK TA1 5DA

Publisher

Wiley

Subject

Pharmacology (medical)

Reference80 articles.

1. Kaye SB ICEBERG3 http://clinicaltrials.gov/show/NCT00628251

2. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer;Kaye;Journal of Clinical Oncology,2012

3. Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer;Kummar;Clinical Cancer Research,2015

4. Randomized trial of oral cyclophosphamide © with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma. 2012 ASCO Annual Meeting;Kummar;Journal of Clinical Oncology,2012

5. Ledermann J Assessment of efficacy of AZD2281 in platinum sensitive relapsed serous ovarian cancer http://clinicaltrials.gov/show/NCT00753545

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expected role of photodynamic therapy to relieve skin damage in nuclear or radiological emergency: Review;Environmental Toxicology and Pharmacology;2024-09

2. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

3. Extracellular Vesicles in Ovarian Cancer: From Chemoresistance Mediators to Therapeutic Vectors;Biomedicines;2024-08-09

4. Prescribers and patients drive maintenance therapy patterns in a community oncology practice: National guidelines versus the real-world experience;Gynecologic Oncology Reports;2024-08

5. Probiotics alleviate paraneoplastic thrombocythemia of ovarian cancer: A randomized placebo-controlled trial;Journal of Functional Foods;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3